NMD Pharma

NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence.